Aarey Drugs & Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
AAREYDRUGS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aarey Drugs reported FY26 revenue of Rs. 47,227 Lakhs, marginally down from Rs. 47,394 Lakhs in FY25. Profit after tax declined slightly to Rs. 396.76 Lakhs from Rs. 402.39 Lakhs, while EPS fell to Rs. 1.39 from Rs. 1.42. The company manufactures bulk drugs and deals in chemical solvents. Q4 standalone PAT was Rs. 155.74 Lakhs on revenue of Rs. 18,947 Lakhs. Statutory auditors Motilal & Associates LLP issued an unmodified (clean) opinion. The auditors noted in an Emphasis of Matter that debtor and creditor balances are subject to confirmation and relied upon management representation. No deviation was reported in utilization of Rs. 797.50 Lakhs raised through convertible warrants preferential issue.
Flat revenue and slight profit decline may keep the stock range-bound. The clean audit opinion and consistent operating cash flow of Rs. 1,014 Lakhs provide some comfort, though the Emphasis of Matter on receivables confirmation warrants monitoring.